Survival and Prognostic Factors in Elderly Patients Receiving Second-line Chemotherapy for Relapsed Small-Cell Lung Cancer: Results from the Japanese Joint Committee of Lung Cancer Registry

Small-cell lung cancer (SCLC) accounts for approximately 12% of lung cancers [1]. Although SCLC is highly sensitive to first-line treatment, about 80% of limited-disease patients and almost all patients with extended disease show disease relapse or progression due to the emergence of drug-resistant tumor cells [2 –5]. Japan is presently aging at a rapid pace, and approximately 50% of all patients with SCLC in Japan are aged>70 years [6]. Advanced age is associated with an increased risk of lung cancer, and the increase in global life expectancy has resulted in a corresponding increase in the incidence of lung cancer.

Source: Lung Cancer - June 4, 2020 Category: Cancer & Oncology Authors: Satoshi Igawa, Katsuhiko Naoki, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino Source Type: research